Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Smit · SciRah

Researcher profile · Semantic Scholar

E. Smit

Share profile

E. Smit — researcher profile on SciRah

h-index: 103
Works: 775
Citations: 45K

Most-cited papers

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Koichi Goto, Y. Goto, T. Kubo, K. Ninomiya +20 more
2023Journal of Clinical Oncology283 citations Open access
Semantic Scholar
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
C. Powell, S. Modi, H. Iwata, S. Takahashi +9 more
2022ESMO Open269 citations Open access
Semantic Scholar
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
S. Oosting, A. V. D. van der Veldt, C. Geurtsvankessel, R. Fehrmann +19 more
2021The Lancet Oncology142 citations Open access
Semantic Scholar
Detection and localization of early- and late-stage cancers using platelet RNA.
Sjors In 't Veld, M. Arkani, Edward Post, Mafalda Antunes-Ferreira +112 more
2022Cancer Cell128 citations Open access
Semantic Scholar
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer
J. Mazières, P. Paik, M. Garassino, X. Le +18 more
2023JAMA Oncology122 citations Open access
Semantic Scholar
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
S. Aix, T. Ciuleanu, A. Navarro, S. Cousin +29 more
2022The Lancet Respiratory Medicine104 citations Open access
Semantic Scholar
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
J. Smit, F. J. Borm, A. Niemeijer, M. Huisman +9 more
2021Journal of Nuclear Medicine90 citations Open access
Semantic Scholar
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
X. Le, H. Sakai, E. Felip, R. Veillon +26 more
2021Clinical Cancer Research85 citations Open access
Semantic Scholar
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer
Gregory Riely, E. Smit, M. Ahn, E. Felip +21 more
2023Journal of Clinical Oncology71 citations Open access
Semantic Scholar
Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
J. van de Haar, L. Hoes, P. Roepman, M. Lolkema +7 more
2021Nature Medicine65 citations Open access
Semantic Scholar
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
L. Hoes, J. M. van Berge Henegouwen, H. van der Wijngaart, L. Zeverijn +26 more
2022Clinical Cancer Research61 citations Open access
Semantic Scholar
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
A. Cortot, X. Le, E. Smit, S. Viteri +7 more
2022Clinical Lung Cancer49 citations Open access
Semantic Scholar
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Z. Piotrowska, D. S. Tan, E. Smit, A. Spira +11 more
2023Journal of Clinical Oncology48 citations Open access
Semantic Scholar
Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy
S. Trebeschi, Z. Bodalal, T. Boellaard, Teresa M. Tareco Bucho +11 more
2021Frontiers in Oncology46 citations Open access
Semantic Scholar
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
M. Jebbink, A. D. de Langen, K. Monkhorst, M. Boelens +10 more
2023JTO Clinical and Research Reports34 citations Open access
Semantic Scholar
Tobacco smoking related mutational signatures in classifying smoking associated and non-smoking associated non-small cell lung cancer.
S. M. Ernst, J. Mankor, J. van Riet, J. H. von der Thüsen +6 more
2022Journal of Thoracic Oncology33 citations Open access
Semantic Scholar
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
K. Hummelink, V. van der Noort, M. Muller, R. Schouten +14 more
2022Clinical Cancer Research32 citations Open access
Semantic Scholar
Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
M. Krzakowski, Shun Lu, S. Cousin, E. Smit +11 more
2022Journal of Clinical Oncology30 citations
Semantic Scholar
Analysis of serious weight gain in patients using alectinib for ALK positive lung cancer.
S. D. de Leeuw, M. Pruis, B. Sikkema, M. Mohseni +8 more
2023Journal of Thoracic Oncology28 citations Open access
Semantic Scholar
Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).
H. Yu, D. S. Tan, E. Smit, A. Spira +13 more
2022Journal of Clinical Oncology28 citations
Semantic Scholar
Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).
Z. Piotrowska, H. Yu, J. Yang, M. Koczywas +14 more
2021Journal of Clinical Oncology28 citations
Semantic Scholar
Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors.
F. Tohidinezhad, D. Bontempi, Zhen Zhang, A. Dingemans +11 more
2023European Journal of Cancer27 citations Open access
Semantic Scholar
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
C. Steuer, H. Hayashi, Wu-Chou Su, M. Nishio +16 more
2022Journal of Clinical Oncology25 citations
Semantic Scholar
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.
L. Zeverijn, S. B. van Waalwijk van Doorn-Khosrovani, A. Van Roy, L. Timmers +12 more
2022The Lancet Oncology25 citations Open access
Semantic Scholar
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
S. Oosting, A. V. D. van der Veldt, R. Fehrmann, C. Geurtsvankessel +18 more
2022The Lancet Oncology24 citations Open access
Semantic Scholar
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
J. M. van Berge Henegouwen, M. Jebbink, L. Hoes, H. van der Wijngaart +13 more
2022European Journal of Cancer24 citations Open access
Semantic Scholar
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.
Aldo A. Acosta-Medina, P. Kemps, T. Zondag, J. Abeykoon +35 more
2023Blood23 citations Open access
Semantic Scholar
Lung Cancer in the Netherlands.
L. Hendriks, A. Dingemans, D. D. De Ruysscher, M. Aarts +8 more
2021Journal of Thoracic Oncology23 citations Open access
Semantic Scholar
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
D. Camidge, T. Morán, I. Demedts, H. Grosch +11 more
2022Clinical Lung Cancer20 citations Open access
Semantic Scholar
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura +16 more
2022Journal of Clinical Oncology19 citations
Semantic Scholar
Real-world insights into patients with advanced NSCLC and MET alterations
M. Bittoni, J. Yang, J. Shih, N. Peled +9 more
2021Lung Cancer18 citations Open access
Semantic Scholar
Real-world utilization of biomarker testing for patients with advanced non-small-cell lung cancer in a tertiary referral center and referring hospitals.
M. van de Ven, H. Koffijberg, V. Retèl, K. Monkhorst +3 more
2021Journal of Molecular Diagnostics18 citations Open access
Semantic Scholar
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
S. Gettinger, R. Huber, Dong-Wan Kim, L. Bazhenova +18 more
2022JTO Clinical and Research Reports17 citations Open access
Semantic Scholar
Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting
R. Boosman, M. Jebbink, W. Veldhuis, S. Groenland +7 more
2022Pharmaceutical Research17 citations Open access
Semantic Scholar
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
D. Tan, Sang-We Kim, S. Ponce Aix, L. Sequist +16 more
2022European Journal of Cancer17 citations Open access
Semantic Scholar
A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer
Hanieh Abedian Kalkhoran, J. Zwaveling, B. Storm, Sylvia A. van Laar +6 more
2023BMC Cancer15 citations Open access
Semantic Scholar
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
R. Veillon, H. Sakai, X. Le, E. Felip +13 more
2022Clinical Lung Cancer15 citations Open access
Semantic Scholar
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
R. ter Heine, M. van den Heuvel, B. Piet, M. Deenen +16 more
2023Targeted oncology14 citations Open access
Semantic Scholar
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging.
Eveline A. van de Stadt, M. Yaqub, A. Lammertsma, A. Poot +6 more
2021Lung Cancer13 citations Open access
Semantic Scholar
Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.
A. van Veelen, J. Gulikers, L. Hendriks, S. Dursun +5 more
2022Lung Cancer12 citations Open access
Semantic Scholar
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
M. Meertens, M. B. Muntinghe-Wagenaar, B. Sikkema, M. Lopez-Yurda +18 more
2023Frontiers in Oncology11 citations Open access
Semantic Scholar
Detection of Circulating Tumor Cells Using the Attune NxT
M. Gruijs, Carolien Zeelen, T. Hellingman, Jasper Smit +8 more
2022International Journal of Molecular Sciences11 citations Open access
Semantic Scholar
LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
G. Riely, M.-J. Ahn, J. Clarke, I. Dagogo-Jack +16 more
2024Annals of Oncology9 citations
Semantic Scholar
First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors
A. Minchom, O. Lindén, D. Knapen, R. Hassan +11 more
2025ESMO Open8 citations Open access
Semantic Scholar
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
G. D. Marijn Veerman, R. Boosman, M. Jebbink, Esther Oomen-de Hoop +13 more
2023EClinicalMedicine8 citations Open access
Semantic Scholar
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
F. J. Borm, Jasper Smit, Joyce Bakker, M. Wondergem +3 more
2023Oncoimmunology8 citations Open access
Semantic Scholar
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
Rolof G. P. Gijtenbeek, V. van der Noort, J. Aerts, Jeske A. Staal-van den Brekel +15 more
2022ERJ Open Research8 citations Open access
Semantic Scholar
The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
P. Joosten, A. D. de Langen, V. van der Noort, K. Monkhorst +5 more
2021Lung Cancer8 citations Open access
Semantic Scholar
Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments
S. Castenmiller, R. de Groot, A. Guislain, K. Monkhorst +5 more
2022bioRxiv7 citations Open access
Semantic Scholar
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
E. Felip, E. Smit, M. Molina-Vila, U. Dafni +18 more
2022Lung Cancer7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Dingemans×10
Invite
A. Dingemans — researcher profile on SciRah
A. D. de Langen×9
Invite
A. D. de Langen — researcher profile on SciRah
E. Felip×7
Invite
E. Felip — researcher profile on SciRah
V. van der Noort×6
Invite
V. van der Noort — researcher profile on SciRah

×6

Invite

L. Hendriks — researcher profile on SciRah

Invite

D. Camidge — researcher profile on SciRah

K. Hartemink×5

Invite

K. Hartemink — researcher profile on SciRah

Invite

P. Paik — researcher profile on SciRah

H. Gelderblom×5

Invite

H. Gelderblom — researcher profile on SciRah

Invite

M. Ahn — researcher profile on SciRah

Dong-Wan Kim×4

Invite

Dong-Wan Kim — researcher profile on SciRah

M. van den Heuvel×4

Invite

M. van den Heuvel — researcher profile on SciRah